Tiger Brokers

热门话题-摩根大通给予“增持”评级，Hims & Hers Health股价上涨

路透中文
Apr 24
热门话题-<a href="https://laohu8.com/S/JPM">摩根大通</a>给予“增持”评级，Hims & Hers Health股价上涨

4月24日 - ** 远程医疗公司Hims & Hers Health（股票代码：HIMS.N）的股价在盘前交易中上涨2.8%，至28.95美元，此前摩根大通首次覆盖HIMS并给予“增持”评级

** 与诺和诺德的合作或将成为转折点，不仅能消除重大的法律风险，还将使该公司定位为提供品牌药、仿制药及复方制剂的综合平台——券商分析

** 该公司在减肥领域的业务今年仍有增长空间——摩根大通

** 此外，更稳定的GLP-1业务、肽类药物合法化、下半年营收加速以及更多品牌合作的可能性，共同构成了面对持怀疑态度的投资者群体时极具吸引力的催化剂路径

** 指出HIMS仍是标普400指数中做空比例最高的个股之一

** 该券商维持HIMS目标价35美元，较上一收盘价有24%的上行空间

** 17家券商中有12家给予“持有”评级，5家给予“买入”评级；目标价中位数为24.5美元

** 截至上一交易日收盘，该股年内累计下跌13.3%

(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10